Morgan Stanley Expects Medtronic, Inc. (MDT) Results at Upper End of Guidance

Morgan Stanley analyst David Lewis reiterated an Overweight rating and $140.00 price target on Medtronic, Inc. (NYSE: MDT) after peer results and commentary suggest ~33-34% organic growth (the upper end of mgmt guidance) is achievable.

The analyst stated "Our sense is management guided for the quarter with intentions to deliver near the high end, and we therefore see ~$8,140mn Cns as the bar to clear, with potential for results in the ~$8,200-$8,300mn range (1-1.5 pts of upside vs. Cns) pending the pace of April recovery."

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $126.70 yesterday.

You May Also Be Interested In

• Medtronic to announce financial results for its second quarter of fiscal year 2027
• Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
• Datadog (DDOG) PT Lowered to $245 at Stifel